Agenus, Inc. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Agenus, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Agenus, Inc. - Product Pipeline Review - 2014', provides an overview of the Agenus, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agenus, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Agenus, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Agenus, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Agenus, Inc.'s pipeline products

Reasons to buy

- Evaluate Agenus, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Agenus, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Agenus, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Agenus, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agenus, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Agenus, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Agenus, Inc. Snapshot 6
Agenus, Inc. Overview 6
Key Information 6
Key Facts 6
Agenus, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Agenus, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Agenus, Inc. - Pipeline Products Glance 14
Agenus, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Agenus, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Agenus, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Agenus, Inc. - Drug Profiles 18
M-200 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
R-100 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
G-100 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
G-200 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
HerpV Vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Antibody Targeting GITR-1 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antibody Targeting OX-40 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Antibody Targeting TIM-3 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody 2 to activate GITR for Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody to Inhibit CTLA-4 for Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody to Inhibit LAG-3 for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody to Inhibit PD-1 for Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Antibody Targeting CXCR3 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Agenus, Inc. - Pipeline Analysis 33
Agenus, Inc. - Pipeline Products by Target 33
Agenus, Inc. - Pipeline Products by Route of Administration 35
Agenus, Inc. - Pipeline Products by Molecule Type 36
Agenus, Inc. - Pipeline Products by Mechanism of Action 37
Agenus, Inc. - Recent Pipeline Updates 39
Agenus, Inc. - Dormant Projects 45
Agenus, Inc. - Discontinued Pipeline Products 46
Discontinued Pipeline Product Profiles 46
AR-177 46
Aroplatin 46
AU-801 46
HSPPC-70 46
Agenus, Inc. - Company Statement 47
Agenus, Inc. - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Agenus, Inc., Key Information 6
Agenus, Inc., Key Facts 6
Agenus, Inc. - Pipeline by Indication, 2014 9
Agenus, Inc. - Pipeline by Stage of Development, 2014 10
Agenus, Inc. - Monotherapy Products in Pipeline, 2014 11
Agenus, Inc. - Partnered Products in Pipeline, 2014 12
Agenus, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
Agenus, Inc. - Phase III, 2014 14
Agenus, Inc. - Phase II, 2014 15
Agenus, Inc. - Preclinical, 2014 16
Agenus, Inc. - Discovery, 2014 17
Agenus, Inc. - Pipeline by Target, 2014 34
Agenus, Inc. - Pipeline by Route of Administration, 2014 35
Agenus, Inc. - Pipeline by Molecule Type, 2014 36
Agenus, Inc. - Pipeline Products by Mechanism of Action, 2014 38
Agenus, Inc. - Recent Pipeline Updates, 2014 39
Agenus, Inc. - Dormant Developmental Projects,2014 45
Agenus, Inc. - Discontinued Pipeline Products, 2014 46
Agenus, Inc., Subsidiaries 49